ZOLL Medical Corporation on Tuesday announced a definitive agreement to acquire Cardiac Science Corporation (CSC), a portfolio company of Aurora Resurgence, a Los Angeles-based private equity investment firm, for an undisclosed value.
With executive offices in Deerfield, Wisconsin, Cardiac Science Corporation (CSC) is leading provider of automated external defibrillators (AEDs), related services and accessories.
The company said sudden cardiac arrest (SCA), an abrupt disruption of the heart's function, which causes a lack of blood flow to vital organs, claims more than 350,000 lives each year in the US. If a victim does not receive CPR and early defibrillation from an AED, chances of survival decrease 10% with each passing minute.
ZOLL's lifesaving AED management programme technology reportedly enables dispatchers to communicate the locations of registered AEDs to callers reporting potential sudden cardiac arrest incidents.
Hence, Cardiac Science's addition to ZOLL's AED Link programme will allow more 9-1-1 agencies to help put AEDs in the hands of laypersons and first responders to support life-saving action.
ZOLL Medical develops and markets medical devices and software solutions to advance emergency care and save lives and part of Asahi Kasei Group company.
Bayer and Broad Institute extend cardiovascular research alliance to advance precision therapies
CirCode Biomed's IND application for HM2002 receives FDA clearance
CeleCor Therapeutics completes Phase 3 trial of new anti-platelet agent for heart attack
Sarepta receives UK approval to continue dosing in ELEVIDYS ENVISION study
Ionis reports positive Phase 3 results for olezarsen in moderate hypertriglyceridemia
Nordic Bioscience launches new Endotrophin assay
AbbVie and ADARx Pharmaceuticals partner on next-generation siRNA therapies
Otsuka's leukaemia drug ponatinib launched on Fangzhou platform
FDA accepts Novo Nordisk's filing application for oral semaglutide 25 mg
Avacta Therapeutics reports positive Phase 1 data for lead candidate
Innovent's limertinib receives Chinese regulatory approval for first-line treatment of lung cancer
Primo Biotechnology's Taoyuan facility granted PIC/S GMP Certification
Renibus Therapeutics completes RBT-1 Phase 3 clinical trial enrolment